Neramexane

• UNSPSC Description:

  Neramexane is an oral N-methyl-D-aspartate (NMDA) receptor antagonist, as a potential neuroprotectant for various central nervous system disorders, including Alzheimer's disease, and for the potential treatment of drug and alcohol dependence, and pain.

• Target Antigen:

  iGluR

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel;Neuronal Signaling

• Assay Protocol:

  https://www.medchemexpress.com/neramexane.html

• Smiles:

  NC1(C)CC(C)(C)CC(C)(C)C1

• Molecular Weight:

  169.31

• References & Citations:

  [1]Rammes G. Neramexane: a moderate-affinity NMDA receptor channel blocker: new prospects and indications. Expert Rev Clin Pharmacol. 2009;2(3):231-238. |[2]Plazas PV, Savino J, Kracun S, et al. Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors. Eur J Pharmacol. 2007;566(1-3):11-19. |[3]Wenk GL, Baker LM, Stoehr JD, Hauss-Wegrzyniak B, Danysz W. Neuroprotection by novel antagonists at the NMDA receptor channel and glycineB sites. Eur J Pharmacol. 1998;347(2-3):183-187.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 3

• CAS Number:

  219810-59-0